• IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease.

  Ma HY, Yamamoto G, Xu J, Liu X, Karin D, Kim JY, Alexandrov LB, Koyama Y, Nishio T, Benner C, Heinz S, Rosenthal SB, Liang S, Sun M, Karin G, Zhao P, Brodt P, Mckillop IH, Quehenberger O, Dennis E, Saltiel A, Tsukamoto H, Gao B, Karin M, Brenner DA, Kisseleva T.
  J Hepatol. 2019 Dec 31. pii: S0168-8278(19)30761-5. doi: 10.1016/j.jhep.2019.12.016.

• High MYC mRNA Expression Is More Clinically Relevant than MYC DNA Amplification in Triple-Negative Breast Cancer.

  Katsuta E, Yan L, Takeshita T, McDonald KA, Dasgupta S, Opyrchal M, Takabe K.
  Int J Mol Sci. 2019 Dec 28;21(1). pii: E217. doi: 10.3390/ijms21010217.

• Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.

  Biswas S, Mandal G, Roy Chowdhury S, Purohit S, Payne KK, Anadon C, Gupta A, Swanson P, Yu X, Conejo-Garcia JR, Bhattacharyya A.
  J Immunol. 2019 Dec 15;203(12):3447-3460. doi: 10.4049/jimmunol.1900692.

• Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4.

  Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Callejas-Valera JL, Vitale-Cross L, Martin D, Amornphimolthan P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS.
  Nat Commun. 2019 Dec 5;10(1):5546. doi: 10.1038/s41467-019-13471-0.

• Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.

  Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger Sm, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D.
  Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5.

• Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.

  Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Dockter T, Tan AD, Beutler A, Loprinzi CL.
  Breast. 2019 Dec;48:89-97. doi: 10.1016/j.breast.2019.09.011.

• Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

  Phelan R, Eissa H, Becktell K, Bhatt N, Kudek M, Nuechterlein B, Pommert L, Tanaka R, Baker KS.
  Curr Oncol Rep. 2019 Nov 25;21(12):104. doi: 10.1007/s11912-019-0861-8.

• Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

  Phelan R, Eissa H, Becktell K, Bhatt N, Kudek M, Nuechterlein B, Pommert L, Tanaka R, Baker KS.
  Curr Oncol Rep. 2019 Nov 25;21(12):104. doi: 10.1007/s11912-019-0861-8.

• Preclinical Characterization of ^86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models.

  Grudzinski JJ, Hernandez R, Marsh I, Patel RB, Aluicio-Sarduy E, Engle J, Morris Z, Bednarz B, Weichert J.
  J Nucl Med. 2019 Nov;60(11):1622-1628. doi: 10.2967/jnumed.118.224808.

• Defining 'T cell exhaustion'.

  Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, Lynn RC, Philip M, Rao A, Restifo NP, Schietinger A, Schumacher TN, Schwartzberg PL, Sharpe AH, Speiser DE, Wherry EJ, Youngblood BA, Zehn D.
  Nat Rev Immunol. 2019 Nov;19(11):665-674. doi: 10.1038/s41577-019-0221-9.

• Immunity to commensal papillomaviruses protects against skin cancer.

  Strickley JD, Messerschmidt JL, Awad ME, Li T, Hasegawa T, Ha DT, Nabeta HW, Bevins PA, Ngo KH, Asgari MM, Nazarian RM, Neel VA, Jenson AB, Joh J, Demmehri S.
  Nature. 2019 Oct 30. doi: 10.1038/s41586-019-1719-9.

• AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.

  Trillo-Tinoco J, Sierra RA, Mohamed E, Cao Y, de Mingo-Pulido A, Gilvary DL, Anadon CM, Costich TL, Wei S, Flores ER, Ruffell B, Conejo-Garcia JR, Rodriguez PC.
  Cancer Res. 2019 Oct 1;79(19):5034-5047. doi: 10.1158/0008-5472.CAN-19-0880.

• Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial-Membrane-Coated Nanoparticles.

  Patel RB, Ye M, Carlson PM, Jaquish A, Zangl L, Ma B, Wang Y, Arthur I, Xie R, Brown RJ, Wang X, Sriramaneni R, Kim K, Gong S, Morris ZS.
  Adv Mater. 2019 Oct;31(43):e1902626. doi: 10.1002/adma.201902626.

• The empirical likelihood prior applied to bias reduction of general estimating equations.

  Vexler A, Zou L, Hutson AD.
  Comput Stat Data Anal. 2019 Oct;138:96-106. doi: 10.1016/j.csda.2019.04.001.

• Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.

  Narayanan S, Kawaguchi T, Peng X, Qi Q, Liu S, Yan L, Takabe K.
  Sci Rep. 2019 Sep 17;9(1):13455. doi: 10.1038/s41598-019-49878-4.

• MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.

  Hata T, Rajabi H, Takahashi H, Yasumizu Y, Li W, Jin C, Long MD, Hu Q, Liu S, Fushimi A, Yamashita N, Kui L, Hong D, Yamamoto M, Miyo M, Hiraki M, Maeda T, Suzuki Y, Samur MK, Kufe D.
  Cancer Res. 2019 Sep 13. pii: canres.1034.2019. doi: 10.1158/0008-5472.CAN-19-1034.

• Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.

  Heath BR, Michmerhuizen NL, Donnelly CR, Sansanaphongpricha K, Sun D, Brenner JC, Lei YL.
  J Dent Res. 2019 Sep;98(10):1073-1080. doi: 10.1177/0022034519864112.

• MUC1-C represses the RASSF1A tumor suppressor in human carcinoma cells.

  Rajabi H, Hata T, Li W, Long MD, Hu Q, Liu S, Raina D, Kui L, Yazumizu Y, Hong D, Samur M, Kufe D.
  Oncogene. 2019 Aug 21. doi: 10.1038/s41388-019-0940-1.

• Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.

  Newton JM, Hanoteau A, Liu HC, Gaspero A, Parikh F, Gartrell-Corrado RD, Hart TD, Laoui D, Van Ginderachter JA, Dharmaraj N, Spanos WC, Saenger Y, Young S, Sikora AG.
  J Immunother Cancer. 2019 Aug 13;7(1):216. doi: 10.1186/s40425-019-0698-6.

• Immune Activation in Mismatch Repair Deficient Carcinogenesis: More Than Just Mutational Rate.

  Willis JA, Reyes-Uribe L, Chang K, Lipkin SM, Vilar E.
  Clin Cancer Res. 2019 Aug 5. pii: clincanres.0856.2019. doi: 10.1158/1078-0432.CCR-18-0856.

• Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer.

  Conejo-Garcia JR
  J Clin Invest. 2019 Jul 29;130:3521-3523. doi: 10.1172/JCI130316.

• Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

  Wu V, Yeerna H, Nohata N, Chiou J, Harismendy O, Raimondi F, Inoue A, Russell RB, Tamayo P, Gutkind JS.
  J Biol Chem. 2019 Jul 19;294(29):11062-11086. doi: 10.1074/jbc.REV119.005601.

• Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation.

  Shalapour S, Karin M.
  Immunity. 2019 Jul 16;51(1):15-26. doi: 10.1016/j.immuni.2019.06.021.

• Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.

  Miyauchi S, Kim SS, Pang J, Gold KA, Gutkind JS, Califano JA, Mell LK, Cohen EEW, Sharabi AB.
  Clin Cancer Res. 2019 Jul 15;25(14):4211-4223. doi: 10.1158/1078-0432.CCR-18-0871.

• Integration of probabilistic regulatory networks into constraint-based models of metabolism with applications to Alzheimer's disease.

  Yu H, Blair RH.
  BMC Bioinformatics. 2019 Jul 10;20(1):386. doi: 10.1186/s12859-019-2872-8.

• PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.

  Saglam O, Zhou J, Wang X, Conejo-Garcia JR.
  Int J Gynecol Pathol. 2019 Jul 3. doi: 10.1097/PGP.0000000000000623.

• Whole-Exome Sequencing Of Ovarian Cancer Families Uncovers Putative Predisposition Genes.

  Zhu Q, Zhang J, Chen Y, Hu Q, Shen H, Huang RY, Liu Q, Kaur J, Long M, Battaglia S, Eng KH, Lele SB, Zsiros E, Villella J, Lugade A, Yao S, Liu S, Moysich K, Odunsi KO.
  Int J Cancer. 2019 Jul 2. doi: 10.1002/ijc.32545.

• Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer.

  Tracz-Gaszewska Z, Dobrzyn P.
  Cancers (Basel). 2019 Jul; 11(7): 948.

• Integrative molecular characterization of resistance to neoadjuvant chemoradiation in rectal cancer.

  Kamran SC, Lennerz JK, Margolis CA, Liu D, Reardon B, Wankowicz SA, Van Seventer EE, Tracy A, Wo JY, Carter SL, Willers H, Corcoran RB, Hong TS, Van Allen EM.
  Clin Cancer Res. 2019 Jun 28. pii: clincanres.0908.2019. doi: 10.1158/1078-0432.CCR-19-0908.

• Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

  Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.
  J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6.

• TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion.

  Seo H, Chen J, Gonzalez-Avalos E, Samaniego-Castruita D, Das A, Wang YH, Lopez-Moyado IF, Georges RO, Zhang W, Onodera A, Wu CJ, Lu LF, Hogan PG, Bhandoola A, Rao A.
  Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12410-12415. doi: 10.1073/pnas.1905675116.

• Illuminating G-Protein-Coupling Selectivity of GPCRs.

  Inoue A, Raimondi F, Kadji FMN, Singh G, Kishi T, Uwamizu A, Ono Y, Shinjo Y, Ishida S, Arang N, Kawakami K, Gutkind JS, Aoki J, Russell RB.
  Cell. 2019 Jun 13;177(7):1933-1947.e25. doi: 10.1016/j.cell.2019.04.044.

• Accurate Quantification of Residual Cancer Cells in Pelvic Washing Reveals Association with Cancer Recurrence Following Robot-Assisted Radical Cystectomy.

  Wei L, Hussein AA, Ma Y, Azabdaftari G, Ahmed Y, Wong LP, Hu Q, Luo W, Cranwell VN, Bunch BL, Kozlowski JD, Singh PK, Glenn ST, Smith G, Johnson CS, Liu S, Guru KA.
  J Urol. 2019 Jun;201(6):1105-1114. doi: 10.1097/JU.0000000000000142.

• HMMRATAC: a Hidden Markov ModeleR for ATAC-seq.

  Tarbell ED, Liu T.
  Nucleic Acids Res. 2019 Jun 14. pii: gkz533. doi: 10.1093/nar/gkz533.

• Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strateg.

  Venkadakrishnan VB, DePriest AD, Kumari S, Senapati D, Ben-Salem S, Su Y, Mudduluru G, Hu Q, Cortes E, Pop E, Mohler JL, Azabdaftari G, Attwood K, Shah RB, Jamieson C, Dehm SM, Magi-Galluzzi C, Klein E, Sharifi N, Liu S, Heemers HV.
  Oncogene. 2019 Jun;38(23):4496-4511. doi: 10.1038/s41388-019-0732-7.

• A robust Pearson correlation test for a general point null using a surrogate bootstrap distribution.

  Hutson AD.
  PLoS One. 2019 May 16;14(5):e0216287. doi: 10.1371/journal.pone.0216287.

• Engineering the TGFβ receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.

  Burga RA, Yvon E, Chorvinsky E, Fernandes R, Cruz CR, Bollard CM.
  Clin Cancer Res. 2019 Apr 22. pii: clincanres.3183.2018. doi: 10.1158/1078-0432.CCR-18-3183.

• MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.

  Yamamoto M, Jin C, Hata T, Yasumizu Y, Zhang Y, Hong D, Maeda T, Miyo M, Hiraki M, Suzuki Y, Hinohara K, Rajabi H, Kufe D.
  Cancer Res. 2019 Apr 15;79(8):2031-2041. doi: 10.1158/0008-5472.CAN-18-3259.

• Preclinical Characterization of ^86/90Y-NM600 in a variety of murine and human cancer tumor models.

  Grudzinski JJ, Hernandez R, Marsh I, Patel R, Aluicio-Sarduy E, ENgle J, Morris Z, Bednarz B, Weichert JP.
  J Nucl Med. 2019 Apr 6. pii: jnumed.118.224808. doi: 10.2967/jnumed.118.224808.

• Cytochrome c Deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.

  Kumar R, Bhat TA, Walsh EM, Chaudhary AK, O'Malley J, Rhim JS, Wang J, Morrison CD, Attwood K, Bshara W, Mohler JL, Yadav N, Chandra D.
  Cancer Res. 2019 Apr 1;79(7):1353-1368. doi: 10.1158/0008-5472.CAN-18-2383.

• Early-onset triple-negative breast cancer in multiracial/ethnic populations: Distinct trends of prevalence of truncation mutations.

  Liu Q, Yao S, Zhao H, Hu Q, Kwan ML, Roh JM, Ambrosone CB, Kushi LH, Liu S, Zhu Q.
  Cancer Med. 2019 Apr;8(4):1845-1853. doi: 10.1002/cam4.2047.

• Deep-learning augmented RNA-seq analysis of transcript splicing.

  Zhang Z, Pan Z, Ying Y, Zhijie X, Adhikari S, Phillips J, Carstens RP, Black DL, Wu Y, Xing Y.
  Nat Methods. 2019 Apr;16(4):307-310. doi: 10.1038/s41592-019-0351-9.

• NR4A transcription factors limit CAR T cell function in solid tumours.

  Chen J, Lopez-Moyado IF, Seo H, Lio CJ, Hempleman LJ, Sekiya T, Yoshimura A, Scott-Browne JP, Rao A.
  Nature. 2019 Mar;567(7749):530-534. doi: 10.1038/s41586-019-0985-x.

• Genomic correlates of response to immune checkpoint blockade.

  Keenan TE, Burke KP, Van Allen EM.
  Nat Med. 2019 Mar;25(3):389-402. doi: 10.1038/s41591-019-0382-x.

• ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.

  Cao Y, Trillo-Tinoco J, Sierra RA, Anadon C, Dai W, Mohamed E, Cen L, Costich TL, Magliocco A, Marchion D, Klar R, Michel S, Jaschinski F, Reich RR, Mehrotra S, Cubillos-Ruiz JR, Munn DH, Conejo-Garcia JR, Rodriguez PC.
  Nat Commun. 2019 Mar 20;10(1):1280. doi: 10.1038/s41467-019-09263-1.

• A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.

  Guram K, Kim SS, Wu V, Sanders PD, Patel S, Schoenberger SP, Cohen EEW, Chen SY, Sharabi AB.
  Front Immunol. 2019 Mar 18;10:491. doi: 10.3389/fimmu.2019.00491.

• Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study.

  Yao S, Hu Q, Kerns S, Yan L, Onitilo AA, Misleh J, Young K, Lei L, Bautista J, Mohamed M, Mohile SG, Ambrosone CB, Liu S, Janelsins MC.
  Clin Epigenetics. 2019 Mar 12;11(1):45. doi: 10.1186/s13148-019-0641-1.

• Discovery of Allele-Specific Protein-RNA Interactions in Human Transcriptomes.

  Bahrami-Samani E, Xing Y.
  Am J Hum Genet. 2019 Mar 7;104(3):492-502. doi: 10.1016/j.ajhg.2019.01.018

• Differences in microRNA expression in breast cancer between women of African and European ancestry.

  Gong Z, Wang J, Wang D, Buas MF, Ren X, Freudenheim JL, Belinsky SA, Liu S, Ambrosone CB, Higgins MJ.
  Carcinogenesis. 2019 Mar 12;40(1):61-69. doi: 10.1093/carcin/bgy134.

• ⁹⁰Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma.

  Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP.
  Commun Biol. 2019 Feb 26;2:79. doi: 10.1038/s42003-019-0327-4.

• Mitochondrial hypoxic stress induces widespread RNA editing by APOBEC3G in natural killer cells.

  Sharma S, Wang J, Alqassim E, Portwood S, Cortes Gomez E, Maguire O, Basse PH, Wang ES, Segal BH, Baysal BE.
  Genome Biol. 2019 Feb 21;20(1):37. doi: 10.1186/s13059-019-1651-1.

• Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.

  Pai CS, Huang JT, Lu X, Simons DM, Park C, Chang A, Tamaki W, Liu E, Roybal KT, Seagal J, Chen M, Hagihara K, Wei XX, DuPage M, Kwek SS, Oh DY, Daud A, Tsai KK, Wu C, Zhang L, Fasso M, Sachidanandam R, Jayaprakash A, Lin I, Casbon Aj, Kinsbury GA, Fong L.
  Immunity. 2019 Feb 19;50(2):477-492.e8. doi: 10.1016/j.immuni.2019.01.006.

• Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

  Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.
  J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

• Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?

  Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M.
  Cell Metab. 2019 Jan 8;29(1):18-26. doi: 10.1016/j.cmet.2018.10.012.

• Leveraging TCR Affinity in Adoptive Immunotherapy against Shared Tumor/Self-Antigens.

  Miller A, Bahmanof M, Zehn D, Cohen E, Schoenberger S.
  Cancer Immunol Res. 2019 Jan;7(1):40-49. doi: 10.1158/2326-6066.